Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Davila

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Blood Advances|February 26, 2021
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantationNelli Bejanyan, Joseph A Pidala, Xuefeng Wang, et al.
Science Translational Medicine|March 22, 2013
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaRenier J Brentjens, Marco L Davila, Isabelle Riviere, et al.
Gastrointestinal Endoscopy|April 26, 2015
Natural language processing as an alternative to manual reporting of colonoscopy quality metricsGottumukkala S Raju, Phillip J Lum, Rebecca S Slack, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood|August 19, 2011
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRenier J Brentjens, Isabelle Rivière, Jae H Park, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Blood Advances|February 26, 2021
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantationNelli Bejanyan, Joseph A Pidala, Xuefeng Wang, et al.
Science Translational Medicine|March 22, 2013
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaRenier J Brentjens, Marco L Davila, Isabelle Riviere, et al.
Gastrointestinal Endoscopy|April 26, 2015
Natural language processing as an alternative to manual reporting of colonoscopy quality metricsGottumukkala S Raju, Phillip J Lum, Rebecca S Slack, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene CiloleucelRawan Faramand, Michael Jain, Verena Staedtke, et al.
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood|August 19, 2011
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRenier J Brentjens, Isabelle Rivière, Jae H Park, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Pageof 13